TECHNOLOGY OFFER

202-13INCREASINGTHEIMMUNERESPONSETOPAPILLOMAVIRUS(HPV)

ü NewHPVdrugü TreatmentofdifferentdiseasescausedbyHPVü Protectstheprogresstohighgradepre-neoplasticorfullymalignantlesions

TheTechnologyThe present invention relates to a DNA demethylatingagent and to a pharmaceutical composition comprisingsaid DNA demethylating agent and carrier for use inincreasing the immune response topapillomavirus (PV).Further, this technic relates toamethodofkillingaPV-infectedcells,comprisingcontactingsaidPV-infectedcellwith a DNA demethylating agent, contacting said PV-infectedcellwithat leastonePVantigenspecificT-cell,and,thereby,killingsaidPV-infectedcell.BackgroundDNAmethylationwas found tohaveaprofound impacton gene expression, with expression of a specific genedecreasingwithanincreaseofthenumberofmethylatedCpG dinucleotides in the vicinity of said gene and itspromoter. Accordingly, DNA methylation has beenidentified as an important regulatorymechanism in thecontrolofgeneexpression, inparticular indevelopmentofmetazoanorganisms.However,DNAmethylationwasalso identified as an important factor in carcinogenesisandinthecellulardefenseagainstviruses.Typically, PVs induce benign hyperproliferative lesions.However,somePV-typescausetheintraepitheliallesionsthatmay progress to high grade pre-neoplastic or evenfullymalignantlesions.PVsvirtuallyavoidcontactwithcellsthatcouldtriggeraspontaneous immune response. This phenomenonexplainswhyitusuallytakesweeksorevenmonthsuntilarobustimmuneresponsebuildsupintheHPV-infectedhost that finally may induce regression of the HPV-infectedlesions.Thus,thereisasubstantialneedintheartforimprovingtheimmuneresponseofanindividualinfectedwithPVinordertopotentiallyeliminatetheinfection.

AdvantagesOnetreatmentfordifferentdiseases,like:warts, exophytic growing papillomas, condylomata,invertedpapillomas,anykindofHPV-inducedsquamousintraepithelial lesions (SIL), other pre-neoplastic orneoplastic PV-induced lesions, cervical neoplasias, skinneoplasias,neoplasiasoftheanalepithelium,neoplasiasof the head and neck region, preferably of theoropharynx,orneoplasiasofthetonsils.CommercialOpportunityü NewHPVdrug

DevelopmentStageü Successfulfirstinhumantreatment

IntellectualPropertyPatentapplication2014WO2015185611A1Contact:technologytransferheidelbergGmbHImNeuenheimerFeld672D-69120HeidelbergGermanyEmail:tt-team@med.uni-heidelberg.de

UniversitätsKlinikum Heidelberg